Gastroenterology Peer Insight Report
Gastroenterologist perspectives on how advanced IBD therapy, intestinal ultrasound, incretin-related GI problems, early-onset colorectal cancer, and emerging microbiome treatments are colliding with real-world practice.
Audience:
Countries:
Survey records: 37
-Hero findings
– Quick Read — Key Findings
Explore the full pattern across advanced IBD sequencing, intestinal ultrasound, GLP-1 related dilemmas, early-onset CRC, and emerging microbiome therapeutics.
Advanced therapies and new diagnostics are changing what gastroenterologists can see and treat. In IBD, new biologic mechanisms and combination strategies raise expectations for deeper control. Intestinal ultrasound offers non-invasive, point-of-care assessment of bowel inflammation. At the same time, widespread incretin use is bringing dysmotility, nausea, and procedural questions into GI clinics, while rising concern about colorectal cancer in younger adults is changing diagnostic caution.
External guidance reflects this broadening role. The American Gastroenterological Association describes intestinal ultrasound as a non-invasive tool that can support objective IBD monitoring, and multi-society guidance around GLP-1 therapies and procedures has shifted toward individualized risk assessment rather than a universal medication-holding rule. These developments make operational readiness part of the clinical story.
The survey shows a specialty negotiating several transitions at once. Respondents are interested in advanced options, but they often keep the newest strategies behind evidence, training, workflow, or risk thresholds. The result is not resistance to innovation. It is selective adoption shaped by what can be defended, delivered, and monitored in daily practice.
Clinical context: American Gastroenterological Association, Intestinal Ultrasound for Inflammatory Bowel Disease; American Gastroenterological Association, Management of GLP-1 Receptor Agonists Prior to Endoscopy; Multi-society guidance on GLP-1 therapy before surgery and GI endoscopy
The survey includes professionals from United States, United Kingdom, Italy, France, Germany.
MDForLives Research Interpretation
A quarter use combination advanced therapy as a frontline option in highly aggressive disease, but 53.1% reserve it for multi-drug refractory cases facing imminent surgery.
What the pattern suggests: Combination therapy has entered practice, but for most respondents it still sits late in the sequence rather than at the beginning.
What may be behind it: Long-term safety evidence, complexity of dual-pathway exposure, and the need to justify escalation may keep a high-efficacy strategy behind a higher clinical threshold.
Why it matters: The gap between therapeutic possibility and routine sequencing is being defined by confidence in durability and safety, not simply by awareness of the approach.
Persistent symptoms narrowly lead at 35.5%, followed closely by incomplete mucosal or transmural healing at 32.3%.
What the pattern suggests: No single endpoint dominates. Patient experience and objective disease control are carrying nearly equal weight in class-switch decisions.
What may be behind it: Moderate-to-severe IBD can produce discordance between symptoms, endoscopy, drug exposure, and biomarkers, so the decision to switch often depends on which signal appears most credible in that patient.
Why it matters: The findings show why treatment sequencing cannot be reduced to one laboratory or imaging threshold. Different forms of incomplete control can lead to the same decision through different routes.
Only 19.4% report full integration, while 74.2% are either partially integrated or planning adoption.
What the pattern suggests: Interest is substantially ahead of complete implementation. The technology appears to have crossed the relevance threshold but not the workflow threshold.
What may be behind it: Training, equipment, scheduling, competency, and image-storage requirements can slow implementation even when clinicians see clear clinical value.
Why it matters: The survey captures an adoption gap that is operational rather than conceptual: many practices want the capability, but fewer have converted that interest into a stable routine.
Severe dysmotility and distinguishing medication effects from disorders of gut-brain interaction each account for 29.0%, with post-treatment metabolic shifts close behind at 25.8%.
What the pattern suggests: The burden is distributed across diagnosis, symptom management, procedures, and treatment transitions rather than clustering around one issue.
What may be behind it: Incretin therapy affects gastric and intestinal function while patients may already have functional GI symptoms, obesity-related disease, or procedural needs, creating overlapping explanations for the same complaint.
Why it matters: Gastroenterologists are increasingly being asked to interpret whether a symptom belongs to the underlying GI disorder, the metabolic therapy, or the interaction between both.
Nearly half report more aggressive diagnostic endoscopy in younger symptomatic patients, while another 32.3% are pushing for lower informal thresholds in high-risk groups.
What the pattern suggests: The main change is not simply earlier population screening. It is a lower tolerance for watchful waiting when a younger patient has potentially relevant symptoms or risk markers.
What may be behind it: The consequences of a missed malignancy can make minor bleeding or altered bowel habits feel less safely attributable to benign disease in younger adults than they did previously.
Why it matters: The survey separates screening age from diagnostic behavior. In practice, symptom-driven investigation can move earlier even when formal population screening thresholds remain unchanged.
Two-thirds are cautiously optimistic and want definitive phase III evidence before prescribing live biotherapeutic products, while 22.6% are already highly optimistic.
What the pattern suggests: The field is open to microbiome therapeutics, but enthusiasm is being held behind a conventional evidence threshold.
What may be behind it: Microbiome interventions face questions about reproducibility, strain standardization, clinical endpoints, durability, and how they perform against established therapies.
Why it matters: The pattern suggests that novelty alone will not drive adoption. Gastroenterologists appear willing to engage, but only when clinical evidence makes the mechanism actionable rather than speculative.
Combination IBD therapy and microbiome therapeutics both show interest without universal early use. The pattern suggests that specialists are distinguishing between scientific promise and evidence they consider mature enough for routine sequencing.
Intestinal ultrasound has a large partial-or-planned adoption pool. The hidden friction may sit in training, scheduling, image storage, and reimbursement rather than in doubt about the technology itself.
Early-onset CRC concern is changing diagnostic behavior more than formal screening policy. The opinions suggest that the threshold for investigation is being recalibrated where the cost of waiting feels harder to justify.
The survey shows gastroenterologists managing several waves of change at once. Advanced IBD combinations, point-of-care imaging, incretin-related GI symptoms, younger colorectal cancer presentations, and microbiome therapeutics each bring a different kind of uncertainty.
The common pattern is selective adoption. Clinicians appear willing to move toward new tools when the evidence and operational pathway feel sufficiently clear, but they preserve higher thresholds when safety, training, or diagnostic ambiguity remains unresolved. The result is a specialty expanding its capabilities while continuously negotiating how much complexity routine practice can absorb.
You have read the summary
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
